Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 13, 2026Blood Cancer Discovery

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

View Full Paper
Ask AI
Bookmark
Share

Authors

DDDimitrios DrekoliasUniversity of South FloridaFZFatima Tuz ZahraUniversity of South FloridaCFCaroline FileniCentre Hospitalier Universitaire de Nice

Discussion

Loading...

Member takes

Implication

Multivariate analysis reveals a prognostic model predicting survival in AML treated with HMA and venetoclax, indicating tailored treatment strategies.

Key Points

  • This research aims to develop a genetics-based prognostic model for acute myeloid leukemia patients treated with venetoclax and hypomethylating agents.
  • Analyzed 506 AML patients at Moffitt Cancer Center treated with HMA/venetoclax.
  • Conducted multivariate analysis on genetic mutations and cytogenetic lesions.
  • Developed a point-based system to stratify patients into risk groups.
  • Identified mutations in TP53, KRAS, JAK2, U2AF1, CBL, and specific cytogenetic lesions as predictors of inferior overall survival.
  • Median overall survival for low-, intermediate-, and high-risk groups was 54.2, 22.3, and 7.5 months, respectively.
  • External validation confirmed prognostic separation with median overall survival of 24.7, 17.4, and 4.3 months.

Cite This Study

Drekolias et al. (2026) studied this question.

synapsesocial.com/papers/698ebf5085a1ff6a93016a60https://doi.org/10.1158/2643-3230.bcd-25-0193
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genetic risk model to predict outcomes for AML treated with HMA and venetoclax2025
  2. 2IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025
  3. 3Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  4. 4Prolonged venetoclax (VEN) plus hypomethylating agent (HMA) therapy in non-promyelocytic AML: A single-centre retrospective cohort study2025
  5. 5Genetic risk stratification in adults with AML receiving venetoclax-based intensive therapy: A real-world study2025